Suppliers and packagers for generic pharmaceutical drug: ZOLMITRIPTAN

ZOLMITRIPTAN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Padagis Israel	ZOLMITRIPTAN	zolmitriptan	SPRAY;NASAL	212469	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-711-91	6 BOTTLE, SPRAY in 1 CARTON (45802-711-91) / 1 SPRAY in 1 BOTTLE, SPRAY (45802-711-00)	2021-11-16
Padagis Israel	ZOLMITRIPTAN	zolmitriptan	SPRAY;NASAL	212469	ANDA	Bryant Ranch Prepack	63629-9575-1	6 BOTTLE, SPRAY in 1 CARTON (63629-9575-1) / 1 SPRAY in 1 BOTTLE, SPRAY (63629-9575-2)	2021-11-16
Padagis Israel	ZOLMITRIPTAN	zolmitriptan	SPRAY;NASAL	212469	ANDA	Bryant Ranch Prepack	71335-2947-1	6 BOTTLE, SPRAY in 1 CARTON (71335-2947-1) / 1 SPRAY in 1 BOTTLE, SPRAY (71335-2947-2)	2021-11-16
Padagis Israel	ZOLMITRIPTAN	zolmitriptan	SPRAY;NASAL	212469	ANDA	Bryant Ranch Prepack	72162-1425-2	6 BOTTLE, SPRAY in 1 CARTON (72162-1425-2) / 1 SPRAY in 1 BOTTLE, SPRAY (72162-1425-4)	2021-11-16
Amneal	ZOMIG	zolmitriptan	SPRAY;NASAL	021450	NDA	Amneal Pharmaceuticals LLC	64896-083-12	6 BOTTLE, SPRAY in 1 CARTON (64896-083-12) / 1 SPRAY, METERED in 1 BOTTLE, SPRAY	2024-07-15
Amneal	ZOMIG	zolmitriptan	SPRAY;NASAL	021450	NDA	Amneal Pharmaceuticals LLC	64896-084-12	6 BOTTLE, SPRAY in 1 CARTON (64896-084-12) / 1 SPRAY, METERED in 1 BOTTLE, SPRAY	2024-07-15
Amneal	ZOMIG	zolmitriptan	SPRAY;NASAL	021450	NDA AUTHORIZED GENERIC	Amneal Pharmaceuticals NY LLC	69238-2351-6	6 BOTTLE, SPRAY in 1 CARTON (69238-2351-6) / 1 SPRAY, METERED in 1 BOTTLE, SPRAY	2024-07-15

ZOLMITRIPTAN SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the global supply chain for Zolmitriptan, a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine. The analysis focuses on key manufacturers of the active pharmaceutical ingredient (API) and critical intermediates, regulatory landscapes, and potential supply chain vulnerabilities.

WHO ARE THE PRIMARY MANUFACTURERS OF ZOLMITRIPIAN API?

The manufacturing of Zolmitriptan API is concentrated among a limited number of global suppliers, primarily located in India and China. These manufacturers often specialize in generic API production and adhere to strict Good Manufacturing Practice (GMP) standards required by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key API manufacturers identified include:

• Aarti Industries Limited: An Indian chemical company with a significant presence in pharmaceutical intermediates and APIs. They produce Zolmitriptan API, catering to both domestic and international markets. Their production facilities are certified by major regulatory authorities.
• Divi's Laboratories Limited: Another prominent Indian API manufacturer known for its large-scale production capacity and strong regulatory compliance. Divi's is a significant supplier for various generic drugs, including Zolmitriptan.
• Sun Pharmaceutical Industries Ltd.: While primarily known as a finished dosage form manufacturer, Sun Pharma also has API manufacturing capabilities and may produce Zolmitriptan API for internal use or external sales.
• Hetero Drugs Limited: A leading Indian pharmaceutical company with a robust API manufacturing arm. Hetero produces a wide range of APIs, and Zolmitriptan is among their offerings.
• Numerous Chinese Manufacturers: A substantial portion of global Zolmitriptan API production originates from China. While specific company names are often less publicly disclosed due to competitive reasons, these manufacturers operate under stringent export regulations and often hold Certificates of Suitability (CEP) or Drug Master Files (DMFs) for their products. Examples of companies that have been associated with this API or similar triptans include Lianhe Chemical Technology Co., Ltd. and Jiangsu Yangnong Chemical Group Co., Ltd.

These companies typically operate large-scale chemical synthesis plants capable of producing Zolmitriptan in multi-ton quantities. Their manufacturing processes involve multiple synthetic steps, requiring precise control over reaction conditions and raw material sourcing.

WHAT ARE THE KEY INTERMEDIATES REQUIRED FOR ZOLMITRIPIAN SYNTHESIS?

The synthesis of Zolmitriptan involves several complex chemical intermediates. The reliable supply of these intermediates is crucial for uninterrupted API production. Fluctuations in the availability or price of these precursor materials can significantly impact the overall Zolmitriptan supply chain.

The primary synthetic route for Zolmitriptan commonly involves the following key intermediates:

• 4-Nitro-1H-imidazole: This is a foundational building block in the synthesis of many imidazole-based compounds. Its availability and purity are critical.
• 5-(Hydroxymethyl)-1H-imidazole-4-carboxamide: This intermediate is often derived from simpler imidazole precursors.
• 3-[(2-Dimethylamino)ethyl]-1H-indole: This indole derivative is a crucial component that is coupled with the imidazole moiety.
• 1-Methylpiperazine: This cyclic amine is attached in a later stage of the synthesis.

The production of these intermediates is also concentrated among specialized chemical manufacturers. Many of these intermediate suppliers are located in regions with established chemical industries, including China and India. Some API manufacturers may produce key intermediates in-house to ensure greater control over their supply chain, while others rely on external suppliers.

The quality and consistency of these intermediates are paramount. Impurities in intermediates can lead to the formation of unwanted byproducts in the final Zolmitriptan API, potentially causing regulatory issues and affecting drug safety and efficacy.

WHAT ARE THE REGULATORY REQUIREMENTS FOR ZOLMITRIPIAN API PRODUCTION?

The manufacturing of Zolmitriptan API is subject to rigorous regulatory oversight by health authorities worldwide. Compliance with these regulations is a prerequisite for market access in major pharmaceutical markets.

Key regulatory considerations include:

• Good Manufacturing Practice (GMP): Manufacturers must adhere to GMP guidelines as defined by the FDA (21 CFR Parts 210 & 211), EMA (EudraLex Volume 4), and other national regulatory bodies. This covers all aspects of production, including facility design, equipment validation, personnel training, quality control, and record-keeping.
• Drug Master Files (DMFs) / Certificates of Suitability (CEPs): API manufacturers typically file DMFs with the FDA and apply for CEPs from the European Directorate for the Quality of Medicines & HealthCare (EDQM). These dossiers contain detailed information about the manufacturing process, controls, and specifications of the API. Pharmaceutical companies developing finished dosage forms reference these filings in their marketing authorization applications.
• Impurity Profiling: Regulatory agencies require comprehensive impurity profiling of the API. Manufacturers must identify, quantify, and control process-related impurities and degradation products to ensure the API's safety and quality. This often involves extensive analytical testing using techniques like High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS).
• Stability Studies: Manufacturers must conduct rigorous stability studies to determine the shelf-life of the Zolmitriptan API under various storage conditions, as per International Council for Harmonisation (ICH) guidelines.
• Site Inspections: API manufacturing facilities are subject to periodic inspections by regulatory authorities to verify ongoing compliance with GMP and other relevant regulations.

The cost and complexity of meeting these regulatory requirements act as a barrier to entry for new manufacturers and favor established players with proven compliance records.

WHAT ARE THE GEOGRAPHICAL CONCENTRATIONS OF ZOLMITRIPIAN API AND INTERMEDIATE PRODUCTION?

The geographical concentration of Zolmitriptan API and intermediate manufacturing significantly influences supply chain dynamics.

• India: This country is a dominant force in generic API manufacturing, including Zolmitriptan. Its strengths lie in its well-established chemical synthesis expertise, a large pool of skilled labor, and a favorable cost structure. Indian manufacturers have a strong track record of regulatory compliance and are major suppliers to Western markets.
• China: China is another critical hub for API and intermediate production. Its vast chemical industry infrastructure and economies of scale allow for competitive pricing. Chinese manufacturers have been increasingly investing in quality systems and regulatory compliance to meet global standards.
• Limited Production in Other Regions: While some niche intermediate production might occur in Europe or North America, the large-scale manufacturing of Zolmitriptan API and its primary intermediates is overwhelmingly concentrated in India and China.

This geographical concentration presents both opportunities and risks. It allows for efficient, large-scale production but also creates dependencies. Disruptions in these regions, whether due to geopolitical events, natural disasters, or localized regulatory crackdowns, can have a global impact on Zolmitriptan availability.

WHAT ARE THE POTENTIAL SUPPLY CHAIN VULNERABILITIES FOR ZOLMITRIPIAN?

The supply chain for Zolmitriptan, like many generic APIs, faces several inherent vulnerabilities:

• Geopolitical Risks: The concentration of manufacturing in India and China makes the supply chain susceptible to geopolitical tensions, trade disputes, or changes in national policies that could restrict exports.
• Regulatory Scrutiny: Increased regulatory oversight or unexpected enforcement actions against specific manufacturing sites in key producing countries can lead to supply disruptions. For example, a facility failing an FDA inspection might be barred from supplying APIs to the US market.
• Raw Material Dependency: The synthesis of Zolmitriptan relies on specific chemical raw materials and intermediates, some of which may have their own limited supplier base. Disruptions in the upstream supply chain for these precursors can halt API production.
• Quality Control Issues: While manufacturers adhere to GMP, isolated incidents of quality control failures or recalls can impact specific batches or suppliers. This necessitates robust quality agreements and auditing by drug product manufacturers.
• Logistical Challenges: Global shipping and transportation networks can be affected by port congestion, freight capacity issues, or unexpected events, leading to delays in product delivery.
• Economic Factors: Fluctuations in currency exchange rates, raw material costs, and labor expenses can impact the pricing and profitability of API manufacturers, potentially affecting supply stability.
• Environmental Regulations: Stricter environmental regulations in manufacturing countries can sometimes lead to temporary shutdowns of chemical plants for compliance upgrades, impacting production volumes.

These vulnerabilities necessitate proactive risk management strategies from pharmaceutical companies, including dual-sourcing, thorough supplier qualification, and maintaining adequate inventory levels of both API and critical intermediates.

HOW DO PATENT EXPIRATIONS AFFECT THE ZOLMITRIPIAN MARKET?

Zolmitriptan was first approved by the FDA in 1997. The patent exclusivity period for the innovator drug (Axert by AstraZeneca) has long expired.

• Generic Competition: The expiration of primary patents allowed for the entry of generic manufacturers into the Zolmitriptan market. This has led to increased competition, driving down prices for both the API and finished dosage forms.
• API Price Dynamics: With multiple generic API suppliers, pricing becomes highly competitive. Manufacturers focus on cost optimization through efficient processes and economies of scale.
• Finished Dosage Form Market: The market for Zolmitriptan tablets is now largely dominated by generic products from various pharmaceutical companies. These companies source their Zolmitriptan API from the global pool of API manufacturers.

The lack of significant ongoing patent protection for Zolmitriptan means that market access is primarily driven by manufacturing efficiency, cost competitiveness, and regulatory compliance rather than intellectual property barriers. This creates a dynamic where pricing and supply reliability are key competitive factors.

WHAT ARE THE KEY DATA POINTS FOR ZOLMITRIPIAN API SUPPLIERS?

Manufacturer	Country of Origin	Key Certifications (Examples)	Product Focus
Aarti Industries Limited	India	US FDA, EDQM (CEP), WHO GMP	Zolmitriptan API, Pharmaceutical Intermediates
Divi's Laboratories Limited	India	US FDA, EMA, PMDA (Japan)	Zolmitriptan API, Other Generic APIs
Sun Pharmaceutical Industries Ltd.	India	US FDA, EMA, PMDA	Zolmitriptan API (internal/external), FDFs
Hetero Drugs Limited	India	US FDA, EMA, WHO GMP	Zolmitriptan API, Wide Range of APIs
Lianhe Chemical Technology Co., Ltd.	China	US FDA, EDQM (CEP)	Pharmaceutical Intermediates, APIs
Jiangsu Yangnong Chemical Group Co., Ltd.	China	US FDA, EDQM (CEP)	Agrochemicals, Pharmaceutical Intermediates

Note: Specific certifications and product offerings can vary and are subject to change. Manufacturers typically maintain up-to-date information on their regulatory filings and product portfolios.

KEY TAKEAWAYS

The Zolmitriptan API supply chain is characterized by a concentration of manufacturers in India and China, who operate under stringent global regulatory frameworks. Key intermediates are also sourced from these regions. The market is driven by generic competition, with pricing and regulatory compliance being paramount. Potential vulnerabilities include geopolitical risks, regulatory scrutiny, upstream raw material dependency, and logistical challenges.

FREQUENTLY ASKED QUESTIONS

1. Are there any novel Zolmitriptan formulations or delivery systems currently in development that might impact API demand? While the primary market for Zolmitriptan is well-established, research into alternative delivery methods or combination therapies can influence future API requirements. However, current market focus is on generic production.

2. What is the typical lead time for ordering Zolmitriptan API from major manufacturers? Lead times can vary significantly based on order volume, current production schedules, and supplier inventory. Generally, orders for multi-kilogram or ton quantities can range from 3 to 6 months.

3. How do manufacturers manage quality assurance for Zolmitriptan API supplied to different regulatory regions (e.g., US vs. EU)? Manufacturers maintain distinct quality systems and documentation packages tailored to the specific requirements of each regulatory authority. This includes meeting specific pharmacopoeial standards (e.g., USP, EP) and providing data that aligns with regional DMF/CEP requirements.

4. What are the primary analytical methods used for quality control of Zolmitriptan API? Key analytical methods include High-Performance Liquid Chromatography (HPLC) for assay and impurity profiling, Gas Chromatography (GC) for residual solvents, Karl Fischer titration for water content, and spectroscopic methods (e.g., IR, UV-Vis) for identity confirmation.

5. How can pharmaceutical companies mitigate the risk of single-source dependency for Zolmitriptan API? Strategies include qualifying multiple API suppliers, conducting thorough audits of potential second sources, establishing robust supply agreements, and maintaining strategic inventory levels of the API.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21 Part 210 & 211. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=210 and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211

[2] European Medicines Agency. (n.d.). EudraLex Volume 4 - Good Manufacturing Practice. Retrieved from https://ec.europa.eu/health/human-use/eudralex

[3] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-monographs-european-pharmacopoeia-cep

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/page/guidelines